A 2.13 Å structure of E-coli dihydrofolate reductase bound to a novel competitive inhibitor reveals a new binding surface involving the M20 loop region

被引:46
作者
Summerfield, Rachael L.
Daigle, Denis M.
Mayer, Stanislas
Mallik, Debasis
Hughes, Donald W.
Jackson, Sean G.
Sulek, Margaret
Organ, Michael G.
Brown, Eric D.
Junop, Murray S.
机构
[1] McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada
[2] Univ Prince Edward Isl, Atlantic Vet Coll, Charlottetown, PE C1A 4P3, Canada
[3] Novartis Inst Biomed Res, Cambridge, MA 02139 USA
[4] York Univ, Dept Chem, N York, ON M3J 1P3, Canada
[5] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada
关键词
D O I
10.1021/jm060570v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Dihydrofolate reductase (DHFR) is a vital metabolic enzyme and thus a clinically prominent target in the design of antimetabolites. In this work, we identify 1,4-bis-{[N-(1-imino-1-guanidino-methyl)]sulfanylmethyl}-3,6-dimethyl-benzene (compound 1) as the correct structure of the previously reported DHFR inhibitor 1,4bis-{(iminothioureidomethyl)aminomethyl}-3,6-dimethyl-benzene (compound 2). The fact that compound 1 has an uncharacteristic structure for DHFR inhibitors, and an affinity (K-I of 11.5 nM) comparable to potent inhibitors such as methotrexate and trimethoprim, made this inhibitor of interest for further analysis. We have conducted a characterization of the primary interactions of compound 1 and DHFR using a combination of X-ray structure and SAR analysis. The crystal structure of E. coli DHFR in complex with compound 1 and NADPH reveals that one portion of this inhibitor exploits a unique binding surface, the M20 loop. The importance of this interface was further confirmed by SAR analysis and additional structural characterization.
引用
收藏
页码:6977 / 6986
页数:10
相关论文
共 20 条
[1]   INHIBITION OF DIHYDROFOLATE-REDUCTASE - EFFECT OF REDUCED NICOTINAMIDE ADENINE-DINUCLEOTIDE PHOSPHATE ON THE SELECTIVITY AND AFFINITY OF DIAMINOBENZYLPYRIMIDINES [J].
BACCANARI, DP ;
DALUGE, S ;
KING, RW .
BIOCHEMISTRY, 1982, 21 (20) :5068-5075
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[4]   Consideration of the pH-dependent inhibition of dihydrofolate reductase by methotrexate [J].
Cannon, WR ;
Garrison, BJ ;
Benkovic, SJ .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 271 (04) :656-668
[5]   Energetically most likely substrate and active-site protonation sites and pathways in the catalytic mechanism of dihydrofolate reductase [J].
Cummins, PL ;
Gready, JE .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2001, 123 (15) :3418-3428
[6]  
DELANO WL, 2002, PYMOL MOL GRAPHICS
[7]   CONSTRUCTION AND EVALUATION OF THE KINETIC SCHEME ASSOCIATED WITH DIHYDROFOLATE-REDUCTASE FROM ESCHERICHIA-COLI [J].
FIERKE, CA ;
JOHNSON, KA ;
BENKOVIC, SJ .
BIOCHEMISTRY, 1987, 26 (13) :4085-4092
[8]   Inhibitors of dihydrofolate reductase in leishmania and trypanosomes [J].
Gilbert, IH .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2002, 1587 (2-3) :249-257
[9]   THE METHOTREXATE STORY - A PARADIGM FOR DEVELOPMENT OF CANCER CHEMOTHERAPEUTIC-AGENTS [J].
HUENNEKENS, FM .
ADVANCES IN ENZYME REGULATION, VOL 34, 1994, 34 :397-419
[10]   DIHYDROFOLATE-REDUCTASE AS A NEW AFFINITY HANDLE [J].
IWAKURA, M ;
FURUSAWA, K ;
KOKUBU, T ;
OHASHI, S ;
TANAKA, Y ;
SHIMURA, Y ;
TSUDA, K .
JOURNAL OF BIOCHEMISTRY, 1992, 111 (01) :37-45